Carisa De Anda

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

18h-index3.4kcitations54works5.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antimicrobial Resistance in Staphylococcus(21), Bacterial Identification and Susceptibility Testing(15), COVID-19 Clinical Research Studies(13), SARS-CoV-2 and COVID-19 Research(13), Antibiotic Resistance in Bacteria(7)

Publications54 total

Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of <scp>COVID</scp>‐19
Clinical and Translational Science·2025Open Access
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study
Clinical Trials·2025· 1 citedOpen Access
Evaluation of the Content Validity of the COVID-19 Symptoms Daily Diary
Patient Related Outcome Measures·2025Open Access
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Infectious Diseases and Therapy·2024· 1 citedOpen Access
Molnupiravir: Mechanism of action, clinical, and translational science
Clinical and Translational Science·2024· 30 citedOpen Access
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)
Microbiology Spectrum·2024· 2 citedOpen Access
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Infectious Diseases and Therapy·2023· 8 citedOpen Access
Population pharmacokinetics of molnupiravir in adults with <scp>COVID</scp>‐19: Lack of clinically important exposure variation across individuals
CPT Pharmacometrics & Systems Pharmacology·2023· 10 citedOpen Access
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Clinical Infectious Diseases·2023· 16 citedOpen Access
Factors Influencing <scp>COVID</scp>‐19 Risk: Insights From Molnupiravir <scp>Exposure‐Response</scp> Modeling of Clinical Outcomes
Clinical Pharmacology & Therapeutics·2023· 9 citedOpen Access
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection
The Pediatric Infectious Disease Journal·2023· 18 citedOpen Access
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial
The Pediatric Infectious Disease Journal·2023· 25 citedOpen Access
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
Infection·2023· 33 citedOpen Access
Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia
The Journal of Clinical Pharmacology·2022· 6 citedOpen Access
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia and End‐Stage Renal Disease Receiving Intermittent Hemodialysis
The Journal of Clinical Pharmacology·2022· 2 citedOpen Access
Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid
Journal of Infection and Chemotherapy·2022· 4 citedOpen Access
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
Annals of Internal Medicine·2022· 67 citedOpen Access
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19
NEJM Evidence·2021· 124 cited
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
NEJM Evidence·2021· 96 cited
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
New England Journal of Medicine·2021· 1.8k citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Philippe Prokocimer(18), Matthew G. Johnson(14), Michelle Brown(12), Amanda Paschke(12), Edward Fang(10), Anita Das(10), Julie Strizki(9), Jay A. Grobler(8), Christopher Bruno(8), Angela Williams‐Diaz(7), Elizabeth G. Rhee(7), Jiejun Du(6), Hong Wan(5), Joan R. Butterton(5), Laura Puzniak(5), Patricia Carmelitano(5), Wei Gao(4), Myra W. Popejoy(4), Lyn Finelli(4), Kalvin Yu(4)